Affinity Chromatography for Purification of IgG from Human Plasma

Hofbauer, Lucia; Bruckschwaiger, Leopold; Butterweck, Harald Arno; Teschner, Wolfgang

doi:10.5772/36427

Cited by 4 publications

(4 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Possibly, the previous results from small cohorts included patients early in AD pathogenesis and are therefore not comparable with the studies from Bapineuzumab and Solanezumab. Finally, in geriatric patients the use of IVIG is often limited by renal insufficiency [88] and we would not have enough blood donors to supply all upcoming AD patients with IVIG [89] in case that Phase III trials give positive results.…”

Section: Naturally Anti-aβ Antibodies and Ivig Treatment: Is Polyclonmentioning

confidence: 99%

Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets?

2013

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is the most common dementia in the industrialized world, with prevalence rates well over 30% in the over 80-years-old population. The dementia causes enormous costs to the social healthcare systems, as well as personal tragedies for the patients, families and caregivers. AD is strongly associated with Amyloid-beta (Aβ) protein aggregation, which results in extracellular plaques in the brain, and according to the amyloid cascade hypothesis appeared to be a promising target for the development of AD therapeutics. Within the past decade convincing data has arisen positioning the soluble prefibrillar Aβ-aggregates as the prime toxic agents in AD. However, different Aβ aggregate species are described but their remarkable metastability hampers the identification of a target species for immunization. Passive immunotherapy with monoclonal antibodies (mAbs) against Aβ is in late clinical development but recently the two most advanced mAbs, Bapineuzumab and Solanezumab, targeting an N-terminal or central epitope, respectively, failed to meet their target of improving or stabilizing cognition and function. Preliminary data from off-label treatment of a small cohort for 3 years with intravenous polyclonal immunoglobulins (IVIG) that appear to target different conformational epitopes indicate a cognitive stabilization. Thus, it might be the more promising strategy reducing the whole spectrum of Aβ-aggregates than to focus on a single aggregate species for immunization.

show abstract

Section: Naturally Anti-aβ Antibodies and Ivig Treatment: Is Polyclonmentioning

confidence: 99%

Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets?

2013

View full text Add to dashboard Cite

show abstract

“…It interacts with Fc part of Ab but some subclasses of IgG didn't show significant fractionation results. 45,46 Due to low pH, protein A chromatography has been in controversial waters as it causes conformational changes in IgG structure leading to aggregate formation. Fab region folded onto Fc region and reduction of size proved essential for elution (Table 1).…”

Section: Affinity Chromatographymentioning

confidence: 99%

Efficiency of purification techniques of human IgG – a review

Mukhtar¹,

Majeed²,

Naseer³

et al. 2021

JBMOA

View full text Add to dashboard Cite

This review is based on technological trends in IgG purification. Various techniques have been developed to separate antibodies from complex mixtures. Among them are the nonchromatographic and chromatographic techniques. The former consist of techniques such as precipitation, liquid to liquid extraction, and high performance tangential flow filtration. While the latter consist of anion exchange, cation exchange, hydrophobic interaction, immobilized metal affinity, mixed-mode, and bio affinity chromatography. The article also throws light on emerging trend of formulating process buffers to prevent anomalies in the antibodies being purified.

show abstract

“…Considering side effects and economic aspects, more multicenter studies with larger patient samples are necessary before such an expensive and burdensome treatment strategy can be widely recommended. Moreover, IVIG is in limited supply 79 but is an important and lifesaving drug. The ethical considerations of off-label use for AD are therefore the other side of the story.…”

Section: Ivig For Treatment Of Ad: Clinical Evidencementioning

confidence: 99%

“…At present, 3.5 to 5.0 g of IVIG are yielded per liter of plasma by fractionation. Modified purification processes for IVIG have been examined for increasing yield and thus quantity; 79 however, this would also significantly increase manufacturing costs.…”

Section: Ivig: a Limited Productmentioning

confidence: 99%

Intravenous immunoglobulin for the treatment of Alzheimer's disease: current evidence and considerations

Schindowski¹,

Zimmermann²,

Schindowski³

2014

DNND

View full text Add to dashboard Cite

Alzheimer's disease (AD) is a devastating neurodegenerative form of dementia with increasing incidence rates in most countries. AD is characterized by amyloid plaques and neurofibrillary tangles in the brains of AD individuals accompanied by global neuronal loss. The peptide amyloid-β (Aβ) aggregates to amyloid plaques in AD brains. As a result, many therapeutic approaches target Aβ. Human plasma and the plasma product intravenous immunoglobulin (IVIG) contain naturally-occurring anti-Aβ antibodies (Nabs-Aβ) that appear to reduce risks of developing AD. IVIG sequesters Aβ and thus interferes with AD progression. This study reviews the role of different Aβ species, Nabs-Aβ, preclinical data, and clinical studies of IVIG as potential AD treatments. The focus of this study is the outcomes of a recent Gammaglobulin Alzheimer's Partnership Phase III trial that did not reach primary endpoints, as well as efforts to compare IVIG with current anti-Aβ monoclonals such as bapineuzumab, solanezumab, and BIIB037. Moreover, this study critically examines current market and ethical consequences of potential off-label uses of IVIG, limits in IVIG supply, and subsequent challenges.

show abstract

Affinity Chromatography for Purification of IgG from Human Plasma

Cited by 4 publications

References 58 publications

Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets?

Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets?

Efficiency of purification techniques of human IgG – a review

Intravenous immunoglobulin for the treatment of Alzheimer's disease: current evidence and considerations

Contact Info

Product

Resources

About

Affinity Chromatography for Purification of IgG from Human Plasma

Cited by 4 publications

References 58 publications

Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets?

Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets?

Efficiency of purification techniques of human IgG – a review

Intravenous immunoglobulin for the treatment of Alzheimer&#39;s disease: current evidence and considerations

Contact Info

Product

Resources

About

Intravenous immunoglobulin for the treatment of Alzheimer's disease: current evidence and considerations